1. Home
  2. SPOK vs HELP Comparison

SPOK vs HELP Comparison

Compare SPOK & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spok Holdings Inc.

SPOK

Spok Holdings Inc.

N/A

Current Price

$11.83

Market Cap

267.8M

ML Signal

N/A

HELP

Cybin Inc. Common Stock

N/A

Current Price

$7.82

Market Cap

303.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SPOK
HELP
Founded
2004
N/A
Country
United States
Canada
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
267.8M
303.9M
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
SPOK
HELP
Price
$11.83
$7.82
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$14.00
N/A
AVG Volume (30 Days)
136.3K
570.6K
Earning Date
05-28-2026
01-01-0001
Dividend Yield
9.08%
N/A
EPS Growth
N/A
N/A
EPS
0.62
N/A
Revenue
$137,653,000.00
N/A
Revenue This Year
$5.28
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$22.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.26
$5.76
52 Week High
$19.31
$8.23

Technical Indicators

Market Signals
Indicator
SPOK
HELP
Relative Strength Index (RSI) 27.29 62.10
Support Level N/A $7.33
Resistance Level $13.68 $8.23
Average True Range (ATR) 0.39 0.60
MACD -0.09 0.18
Stochastic Oscillator 6.00 95.65

Price Performance

Historical Comparison
SPOK
HELP

About SPOK Spok Holdings Inc.

Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.

Share on Social Networks: